Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Phase: PHASE2
Conditions: Anorexia Nervosa, Osteoporosis
Sponsor: Massachusetts General Hospital

 
Transdermal Estrogen in Older Premenopausal Women With Anorexia 
Nervosa 
 
             NCT02475265 
 
 Version Date: 8/30/2018 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 1 of 11 
 
 
PARTNERS HUMAN RESEARCH COMMITTEE 
DETAILED PROTOCOL 
 
I. 
BACKGROUND AND SIGNIFICANCE 
 
Anorexia nervosa (AN) is a prevalent psychiatric disorder affecting up to 1% of college-aged 
women in the US (1) and an increasing number of women over 30 years of age (2).  AN is 
characterized by self-imposed starvation and is associated with significant medical complications 
which lead to increased morbidity and mortality (3).  Among the many medical co-morbidities 
associated with AN, the most common is significant bone loss, which can persist despite weight 
recovery (4).  Nearly 50% of women with AN have osteopenia with an additional 30% meeting 
WHO criteria for osteoporosis (5, 6).  Importantly, this severe bone loss is associated with an 
increased fracture risk.  Nearly 30% of women with AN report a history of a fracture (6) and a 
prospective study demonstrated a 7-fold increased risk of fracture in women with AN compared 
to age-matched controls (7).  Because AN is a chronic disease that can persist despite psychiatric 
and nutritional counseling, the bone loss and increased fracture risk can persist and lead to 
lifelong morbidity.  A population-based retrospective study demonstrated the cumulative 
incidence of fracture, even many years after the diagnosis of AN, to be 57% (8).  Therefore, 
finding a treatment for bone loss associated with AN is of critical importance.   
 
Loss of bone mass in AN results from hormonal alterations in response to chronic nutritional 
deprivation. The body responds to caloric deprivation by trying to prevent unnecessary energy 
expenditure.  During periods of decreased caloric availability, reproduction and growth become 
less important for the survival of an organism and therefore these processes are down-regulated.  
In AN, down-regulation of the reproductive axis results in hypoestrogenemia.  Low estrogen 
states, such as menopause, result in increased bone resorption (9) and therefore the 
hypoestrogenemia characteristic of AN is a significant contributor to the loss of bone mass.  This 
is supported by the fact that duration of amenorrhea is inversely associated with bone mineral 
density (BMD) in AN (10).  Despite this association, initial studies investigating the effects of 
oral estrogen in AN did not show benefit (11, 12).  This is hypothesized to be due to the fact that 
oral estrogen suppresses IGF-I production (13, 14), an important bone trophic factor.  Patients 
with AN are relatively IGF-I deficient and low systemic IGF-I levels are an important 
mechanism of bone loss in AN.  In humans, systemic IGF-I is produced primarily by the liver 
under the regulation of growth hormone as well as nutritional status.  Systemic IGF-I levels in 
AN are approximately 50% those of normal weight women or weight-recovered women with a 
history of AN (15).  In animal models, systemic and tissue levels of IGF-I are important for the 
acquisition of bone mass (16-18) and in humans, low systemic IGF-I levels are associated with 
low BMD in AN (19) and treatment with rhIGF-I leads to small increases in BMD in women 
with AN (12).  Therefore further suppression of IGF-I by oral estrogen may contribute to further 
bone loss in AN. 
 
Importantly, transdermal, physiologic estrogen replacement does not suppress systemic IGF-I 
production.  Oral estrogen has significant hepatic effects and these effects are bypassed when the 
estrogen is administered transdermally.  Importantly, oral but not transdermal estrogen 
suppresses hepatic IGF-I synthesis; in contrast, transdermal estrogen replacement has been 
shown to increase IGF-I levels in post-menopausal women (13, 20).  The dose of estrogen is also 
an important factor in IGF-I suppression, such that higher doses of oral estrogen have greater 
Version Date: 8/30/2018 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 2 of 11 
 
suppressive effects on IGF-I production (14) and therefore, the supraphysiologic doses of 
estrogen found in oral contraceptive pills suppress IGF-I to a greater degree than physiologic 
doses of oral estrogen. 
 
Understanding the effects of transdermal estrogen on a population of older, premenopausal 
women with AN will be critical in order to provide potential treatment options for this 
population.  Although physiologic and supraphysiologic doses of oral estrogen do not increase 
BMD in women with AN, when compared to placebo (11, 12), physiologic, transdermal 
estrogen replacement increases BMD in adolescent girls with AN in as little as 6 months (21).  A 
randomized, placebo-controlled study of 110 adolescent girls with AN treated predominantly 
with transdermal, physiologic estrogen demonstrated a 1.8% increase in lumbar spine (LS)BMD 
after 6 months (compared to a -0.5% loss of LSBMD in the placebo group) (21).  LSBMD 
continued to increase with time, such that a 2.6% increase in LSBMD was observed after 18 
months of treatment.  Yet these data cannot be extrapolated to adults with AN because 
adolescence is a time of bone accrual and in contrast to adult women with AN who have high 
levels of bone resorption (22), adolescent girls with AN are in a state of low bone turnover (23).  
Therefore, whether transdermal estrogen would have the same effect in adult women with AN is 
unknown.    
 
II. 
SPECIFIC AIMS 
 
Specific Aim 1: We hypothesize that administration of transdermal estrogen will increase 
bone mineral density (BMD) and improve parameters of bone microarchitecture and 
strength in osteopenic women with anorexia nervosa (AN) and that response to treatment 
will be predicted by markers of bone resorption 
 
We will investigate in women with AN in a 6-month open-label study whether treatment with 
transdermal estrogen replacement will increase BMD, improve parameters of bone 
microarchitecture, as assessed by HR-pQCT and improve bone strength, as estimated by 
microfinite element analysis and whether these increases are associated with bone turnover 
markers. 
 
Specific Aim 2: We hypothesize that administration of transdermal estrogen will decrease 
vertebral MAT in women with AN and this decrease will be associated with increases in 
BMD 
 
We will investigate in women with AN in a 6-month open-label study whether treatment with 
transdermal estrogen replacement will decrease vertebral MAT, as assessed by 1H-magnetic 
resonance spectroscopy, and whether this decrease in vertebral MAT is associated with increases 
in BMD. 
 
Specific Aim 3: We hypothesize that MAT levels are associated with changes in 
physiological endogenous estrogen in healthy women, and that MAT levels will be the 
highest during the follicular phase of the menstrual cycle and lowest during the luteal 
phase 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 3 of 11 
 
We will investigate in normal-weight women whether changes in endogenous estrogen levels 
during the follicular and luteal phases of menstrual cycles are associated with changes in MAT 
levels, as assessed by 1H-magnetic resonance spectroscopy. 
 
 
III. 
SUBJECT SELECTION 
 
We will screen a total of 50 individuals. We will screen 25 individuals 25-50 years of age with 
AN to study 11 patients for an evaluable 10 patients for six months in this open-label pilot study.  
We will screen 25 normal-weight individuals 21-40 years of age to study 11 patients for an 
evaluable 10 patients for two months in the control study. Recruitment will occur in one of 6 
ways: 1.) Subjects who have participated or screened in previous studies in the Neuroendocrine 
Unit and have asked to be notified of future studies will be contacted.  2.) Newspaper 
advertisements and online advertisements will also be utilized as a potential recruitment strategy.  
3.) Subjects may be identified using the RPDR and their physicians will be contacted and 
provided with information about the study.  4.) RSVP for Health, a registry through which 
interested individuals can register to receive information about clinical trials, will be used to send 
emails and mailings to potential subjects. 5.) We will post flyers advertising the study in 
approved areas of the Massachusetts General Hospital main campus, as well as at gyms and 
exercise studios in the greater Boston area. 6.) A description of the study will be included on the 
“Research Studies” page of the Neuroendocrine Clinical Research Program website, available at 
http://endocrineweb.wix.com/neuroendocrine-unit#!research-studies/cee5.  
 
 
If one of Dr. Fazeli’s own patients is identified as a potential subject, we will contact the patient 
in writing initially, and allow the patient to contact us if they are interested in participating or 
finding out more information about the research study.  
 
Inclusion criteria for AN women: 
- 
Female; ages 25-50 years 
- 
DSM-V psychiatric criteria for AN, and amenorrhea 
- 
T-score of < -1.5 at spine or hip 
- 
Treatment team or treatment professional in place for clinical treatment/monitoring during 
the study 
 
Exclusion criteria for AN women:  
- 
Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin 
D deficiency, Cushing’s syndrome, diabetes mellitus or renal insufficiency 
- 
Personal history of venous or arterial clot 
- 
History of stroke or myocardial infarction 
- 
History of migraine headaches 
- 
History of hypercoagulable disorder 
- 
Personal history or history of a first-degree relative with breast cancer 
- 
History of hereditary angioedema 
- 
Any medication known to affect bone metabolism, including systemic glucocorticoids within 
three months of the baseline visit, depot medroxyprogesterone within 6 months of the 
baseline visit, oral bisphosphonates within one year of the baseline visit or IV 
bisphosphonates within three years of the baseline visit\ 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 4 of 11 
 
- 
Bone fracture within the prior 12 months 
- 
Serum potassium < 3.0 meq/L or serum ALT > 3 times the upper limit of normal 
- 
Fasting serum triglyceride level > 150 mg/dL 
- 
Pregnant or breastfeeding 
- 
Active substance abuse 
- 
The Principal Investigator believes that the subject may not be able to safely complete the 
study 
 
Inclusion criteria for normal-weight women: 
- 
Women between the ages of 21-40 years of age 
- 
90-110% of ideal body weight 
- 
Regular menstrual cycles (21-35 days in length with no more than 5 days of inter-cycle 
variability) for at least 12 months 
- 
Normal thyroid function 
 
Exclusion Criteria for normal-weight women: 
- 
Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin 
D deficiency, Cushing’s syndrome, diabetes mellitus or renal insufficiency 
- 
Personal history of low bone mass 
- 
Bone fracture within the last 12 months 
- 
Pregnancy or nursing within the last 12 months 
- 
Personal history of an eating disorder 
- 
Contraindications to MRI: cardiac pacemaker, metal implants, claustrophobia 
- 
Medication known to affect bone metabolism -- including systemic glucocorticoids -- within 
three months of the study. Patients receiving depot medroxyprogesterone (Depo-Provera) 
will be excluded from participating for one year after their last injection 
- 
History of bisphosphonate use or use of any medication for the treatment of low bone mass 
- 
Active substance abuse 
 
 
IV. 
SUBJECT ENROLLMENT 
 
Informed consent will be obtained from all potential study subjects by a licensed physician 
investigator no later than at the beginning of the screening visit.  At this time, the subject will be 
explicitly counseled that he or she is free to choose whether or not to participate in this study.  
Eligible subjects with anorexia nervosa who choose to participate will be started on a 
transdermal estrogen/progesterone patch (Climara Pro, Bayer HealthCare Pharmaceuticals, Inc) 
at the baseline visit.  All patients will also take a multivitamin which provides 400 IU Vitamin D.  
Patients who do not meet the RDA for calcium, calcium supplementation will be provided in 
order to raise subjects’ calcium intake to 1,200 mg daily.  
 
If individuals who do not speak English express interest in this study, study investigators will 
provide a translator who is fluent in both English and the subject’s native language and either 
submit a translation of the entire PHRC approved English version of the informed consent form 
to the IRB for approval. This is in accordance with the PHRC policy on obtaining and 
documenting informed consent of subjects who do not speak English. 
 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 5 of 11 
 
 
 
V. 
STUDY PROCEDURES 
 
Subjects with Anorexia Nervosa 
For the Screening Visit, subjects will be seen at the MGH clinical research center for an 
outpatient visit to determine eligibility, including medical history/physical exam.  History taking 
will include complete eating disorder, weight, menstrual, medication and fracture histories. The 
following will also be performed: 1. Blood draw for potassium, BUN/creatinine, ALT, thyroid 
function studies, FSH, 25-OH vitamin D, triglyceride level 2. Nutritional evaluation, including 
weight in a gown, height, frame size, calculation of % ideal body weight (% IBW) and BMI, 3. 
Urine pregnancy test, 4. Bone mineral density (BMD) evaluation by dual energy x-ray 
absorptiometry (DXA), 5. Verification of the AN diagnosis and lack of comorbid concerns (i.e. 
suicidality or substance use) will occur by the study psychologist, Dr. Kamryn Eddy.   
 
At the Baseline Visit, the following procedures will be performed: 1.Medical history, physical 
exam, 2. Urine pregnancy test, 3. Nutritional evaluation, including weight in a gown, height, 
calculation of % IBW and BMI, and calculation of daily intake of calcium and vitamin D, 4. 
Exercise history, 5. Blood draw for complete blood count (CBC), reticulocyte count, and 
hormone analyses including P1NP, osteocalcin, Type I collagen C-telopeptide (CTX), 6. BMD 
evaluation by DXA (if baseline visit is not within six weeks of screening visit), 7.Bone 
microarchitecture evaluation by HR-pQCT, 8.MAT assessment by 1H-MRS, 9. Demonstration 
for administration of first physiologic transdermal estrogen/progesterone patch (Climara Pro, 
Bayer HealthCare Pharmaceuticals, Inc) 10. Subjects will receive 400 international units of 
cholecalciferol daily and 1200mg of elemental calcium daily during the study, 11. Hamilton 
Anxiety Rating Scale (HAM-A). 
 
At Month 1, Month 2, Month 4, and Month 5 the study doctor will check in with subjects by 
phone. During a phone check-in, the study doctor will speak with the subject about any changes 
to the subject's health or medical history since the last time they spoke, and address any 
questions or concerns the subject may have. If the study doctor discovers anything concerning 
through a phone check-in, she will make sure that necessary action is taken. 
 
All subjects will return to Massachusetts General Hospital for the Month 3 visit. This visit will 
include the following procedures: 1.Medical history, physical exam, 2. Urine pregnancy test, 3. 
Nutritional evaluation, including weight in a gown, height, calculation of % IBW and BMI, 4. 
Blood draw for CBC, reticulocyte count, and hormone analyses including P1NP, osteocalcin, 
CTX, 5. BMD evaluation of spine by DXA, 6. MAT assessment by 1H-MRS, 7. HAM-A. 
 
Month 6 (Final Study Visit): Subjects will undergo: 1.Medical history, physical exam, 2. Urine 
pregnancy test, 3. Nutritional evaluation, including weight in a gown, height, calculation of % 
IBW and BMI, 4. Blood draw for CBC, reticulocyte count, and hormone analyses including 
P1NP, osteocalcin, CTX, 6. BMD evaluation by DXA, 7. Bone microarchitecture evaluation by 
HR-pQCT, 8. MAT assessment by 1H-MRS, 9. HAM-A. 
 
Baseline, Month 3, and/or Month 6 visits may be divided into two shorter visits, depending on 
scan availability; divided visits will be no more than 10 days apart. 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 6 of 11 
 
 
 
Normal-Weight Subjects 
For the Screening Visit, subjects will be seen at the MGH Clinical Research Center (CRC) for an 
outpatient visit to determine eligibility. The screening visit will consist of a medical history, 
physical exam, laboratory studies, and urine pregnancy test. History taking will include complete 
weight, menstrual, medication, and fracture histories. The following will also be performed: 1) 
Blood draw for comprehensive metabolic panel, thyroid function studies, 25-OH vitamin D; 2) 
Nutritional evaluation, including weight in a gown, height, frame size, calculation of % ideal 
body weight (% IBW) and BMI; 3) Urine pregnancy test; 4) BMD evaluation by dual energy x-
ray absorptiometry (DXA). 
 
Subjects who qualify for the study and choose to enroll will then present for two additional 
visits: Early Follicular Phase Visit (days 3-5 of the menstrual cycle) and Luteal Phase visit (days 
12-21 of the menstrual cycle). At each of these visits, the following procedures will take place: 
1) medical history, physical exam; 2) urine pregnancy test; 3) Nutritional evaluation including 
weight in a gown, height, calculation of % IBW and BMI, and calculation of daily intake of 
calcium and vitamin D; 4) Hormone analyses including P1NP, osteocalcin, Type I collagen C-
telopeptide (CTX); 5) MAT assessment of the lumbar spine (L4) by 1H-MRS. 
 
 
Experimental Endpoints: 
 
Nutritional Status: CRC dietitians will assess the nutritional status of all patients. 
Metabolic weight and height will be determined and percent ideal body weight and BMI 
calculated.  Activity will be assessed using the Paffenbarger assessment.   
  
 
Markers of Bone Turnover: Sensitive blood and urine markers of bone turnover have 
been developed to assess bone remodeling in a noninvasive, reproducible fashion.  We will 
measure both markers of bone formation and markers of bone resorption including osteocalcin, 
P1NP and serum CTX.  
 
 
Marrow Adiposity: Marrow adiposity will be measured by magnetic resonance 
spectroscopy (MRS).  Endpoints will include L4 marrow adiposity, and marrow adiposity of the 
epiphysis, metaphysic and diaphysis of the femur.  Imaging examinations will be performed in 
the Department of Radiology, Yawkey 6th floor or Ellison 2nd floor, using a 1.5T or 3.0T MR 
device (GE Medical Systems, Milwaukee, WI and Siemens, Erlangen, Germany).  Magnetic 
field strengths of 1.5T and 3.0T are approved by the FDA for clinical use. Subjects will be 
required to lie in a magnet for about 1 hr. The 1.5T and 3.0T MR devices are FDA-approved for 
clinical use. 
 
 
Bone Density: Bone density will be measured by DXA of the whole body, hip, wrist and 
lumbar spine (Hologic Discovery A, Hologic, Inc. Waltham, MA) to determine cortical and 
trabecular bone density.  The primary bone mineral density (BMD) endpoint will be the BMD 
measurement of the PA spine.  DXA is a standardized, reproducible method to determine bone 
density and has been used successfully in our previous studies.  It involves minimal radiation 
exposure to the patient. 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 7 of 11 
 
 
Xtreme CT:  Xtreme CT of the wrist and distal tibia will be performed to evaluate bone 
density and bone quality by examining the microarchitecture of the bones of the forearm and 
lower leg and by providing us with information about both the trabecular and cortical 
components. 
 
 
Anxiety: Evaluation of psychic and somatic anxiety will be performed using the 
Hamilton Anxiety Rating Scale.   
 
VI. 
BIOSTATISTICAL ANALYSIS 
 
Change in lumbar spine BMD will be used as the primary endpoint in this study.  The lumbar 
spine is the most frequent and severe site of low BMD in AN (6).  We will measure BMD with 
dual energy x-ray absorptiometry (Discovery A; Hologic, Waltham, MA) at baseline, month 3 
and at the final study visit. 
 
We will also be monitoring changes in parameters of trabecular and cortical bone 
microarchitecture: HR-pQCT will be used to measure volumetric density, morphology and 
microarchitecture at the distal radius and distal tibia by HR-pQCT (Scanco Medical AG®, 
Bassersdorf, Switzerland).  We will measure trabecular and cortical parameters of bone 
microarchitecture at baseline and at the final, 6-month study visit. 
Additionally, we will assess bone strength by finite element (FE) analysis: Bone strength will be 
estimated using FE analysis of HR-pQCT scan data using published, validated techniques (54). 
 
We will be measuring change in marrow adiposity of L4 vertebra: Marrow adipose tissue of the 
L4 vertebra will be measured using 1H-MRS at baseline, month 3 and at the final study visit. 
Statistical Methods: The analyses of these pilot study data will be performed in collaboration 
with Dr. David Schoenfeld, Professor of Biostatistics at the Harvard School of Public Health and 
Professor of Medicine at Harvard Medical School, and a study collaborator. 
 
The primary analysis will be a paired t-test comparing the post-transdermal estrogen lumbar 
spine BMD value to the baseline value.  We will study 11 patients for an evaluable 10 patients 
for 6 months in an open-label study.  With 10 patients, we will have a power of over 80% at a 
two-sided p=0.05 level of significance if the true rate of bone gain is 1.2% (this value is 1/3 less 
than the percent BMD gain found in adolescent girls treated with physiologic estrogen for 6 
months).  This calculation assumes a SD of 1.2%. 
 
The secondary analyses will be paired t-tests comparing the post-transdermal estrogen 
parameters of trabecular microarchitecture, bone strength and marrow adiposity with baseline 
values.  With 10 patients per group, we will have 80% power at a two-sided p=0.05 level of 
significance if the true rate of difference between the treatments is 1.2%, based on an assumption 
that the SD is 1.2%.  There are currently no data looking at the short-term (6 month) effects of 
estrogen replacement on bone microarchitecture or strength in postmenopausal women or girls or 
women with AN and therefore this effect size is an estimate of what might be expected.  In post-
menopausal women, one year of transdermal estrogen replacement resulted in a 20% decrease in 
adipocyte volume (as measured by bone biopsy) (55), therefore we believe that a change of 1.2% 
in marrow adiposity is a conservative estimate of the potential change. 
 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 8 of 11 
 
VII. 
RISKS AND DISCOMFORTS 
 
Transdermal Estrogen/Progesterone: 
The transdermal patch is applied weekly and administers 0.045 mg/day of estradiol along with 
0.015 mg/day of a 2nd generation progestin, levonorgestrel. We believe that a combination patch 
which includes both estradiol and a progestin is the safest way to administer estradiol to a 
population of women with an intact uterus.  Administration of progesterone is necessary to 
prevent against endometrial hyperplasia and endometrial cancer and a patch which contains both 
estradiol and a progestin will prevent the inadvertent use of unopposed estrogen and therefore 
minimize this risk.  Transdermal patches may also be associated with skin irritation at the site of 
administration but are generally very well tolerated. 
 
The risks of exogenous estrogen and progesterone administration include an increased risk of 
pulmonary embolus, deep venous thrombosis, stroke, myocardial infarction (MI) and retinal 
vascular thrombosis (24).  We will therefore exclude any subject who has a personal history of a 
venous or arterial clot, any subject with a history of an MI or stroke, any subject with a history of 
a hypercoagulable disorder and/or a history of migraine headaches (as exogenous estrogen use in 
women with migraines may increase the risk of stroke).  The Climara Pro patch contains a 2nd 
generation progestin, levonorgestrel, which has a lower thrombotic risk than the 3rd or 4th 
generation progestins (25) and replacement-dose transdermal estrogen patches are associated 
with a much lower risk of venous thromboembolism as compared to oral estrogen replacement 
and therefore we believe that the transdermal route will minimize the risk of venous 
thromboembolism (26).  An increased risk of invasive breast cancer has been reported with the 
use of exogenous estrogen as well as an increased risk of abnormal mammograms requiring 
further evaluation.  We will therefore exclude any individual with a personal history or a first-
degree relative with a history of breast cancer.   
 
Blood Sampling: 
Blood sampling is performed in the study and there is always a very minor risk of infection, 
bruising, or syncope during a blood draw.  There is also the discomfort of having one’s blood 
drawn.   
 
Radiation: 
A portion of this research study involves exposure to radiation. The total radiation dose the AN 
subjects will receive from three or four DXA scans and two HR-pQCT scans is 0.12 milliSievert 
(mSV).  This amount of radiation is approximately 4% of the yearly natural background 
radiation from the earth and the sky (equivalent to 15 days of background radiation).  The total 
radiation dose the normal-weight subject will receive from one DXA scan is 0.03 mSV This 
amount of radiation is less than 1% of the yearly natural background radiation from the earth and 
the sky (equivalent to 4 days of background radiation). There are no known health risks 
associated with such a dose.   
 
Confidentiality: 
The study staff will stringently protect the confidentiality and privacy of the study subjects by 
keeping all data in locked offices and/or password protected offices.  There is a rare risk of loss 
of confidentiality but study staff will do our best to prevent  
 
 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 9 of 11 
 
 
VIII. 
POTENTIAL BENEFITS  
 
The AN subjects’ bone mineral density may increase during the study, although if it does 
increase, it is not known how long it will remain increased.  We hope and anticipate that the 
information learned from this study will allow us to better understand the pathophysiology of 
bone loss in AN and to improve the treatment of patients with bone loss associated with under-
nutrition.  
 
There will be no benefits to the normal-weight subjects, but we hope that information learned 
from this study will allow us to better understand the factors affecting marrow adipose tissue, its 
association with mineral metabolism, and its possible function in the bone marrow 
microenvironment. 
 
IX. 
MONITORING AND QUALITY ASSURANCE 
 
A number of procedures will be instituted to protect against the potential risks involved in this 
protocol.  All patients will have a pregnancy test on admission prior to being exposed to 
radiation or receiving study medication and at each study visit thereafter. Bone density 
measurements will be made three times over the course of 6 months. Xtreme CT measurement 
will be made two times over the course of six months. The combined radiation from such 
procedures is less than 1% of the background radiation in one year.  Confidentiality of the 
patients will always be of paramount importance to study investigators.  All data on patients will 
be kept in confidential study binders accessed by only study investigators in locked rooms.  No 
data on study subjects will be shared with persons other than those directly involved in the study, 
except at the documented request of the patient.  Counseling will be made available by a study 
psychiatrist or psychologist. 
 
A Safety Monitor will be established at MGH.  The Monitor will consist of study investigators 
and an independent clinical expert in mineral metabolism at MGH, Dr. Lisa Nachtigall.  The 
study investigators will review the safety data weekly to ensure the safety of the participants in 
the study and the Monitor will meet every six months, or more often as needed.  The Monitor 
will review all study procedures, all adverse events, study violations, exceptions and deviations 
as well as study inclusion and exclusion criteria.  The Monitor will review all safety monitoring 
blood tests and study data as available.  All study related serious adverse events will be reported 
to the Monitor within 24h of occurrence.  All unanticipated problems, including adverse events 
will be reported to the Partners Human Research Committee (PHRC) according to Partners 
reporting policy and to the FDA according to Title 21 of the Code of Federal Regulations.  All 
unanticipated problems, including adverse events will be reported to the Safety Monitor and the 
report of the Monitor meetings will be submitted to the Partners Human Research Committee 
semi-annually. 
 
X. 
REFERENCES 
 
1. 
Lucas AR, Crowson CS, O'Fallon WM, Melton LJ, 3rd 1999 The ups and downs of 
anorexia nervosa. Int J Eat Disord 26:397-405 
2. 
Trickey H 2006 Eating disorders exact toll on adults, too. www.cnn.com 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 10 of 11 
 
3. 
Association AP 1994 Diagnostic and statistical manual of mental disorders (DSM-IV).  
4th edition:Washington, DC 
4. 
Herzog W, Minne H, Deter C, Leidig G, Schellberg D, Wuster C, Gronwald R, 
Sarembe E, Kroger F, Bergmann G, et al. 1993 Outcome of bone mineral density in 
anorexia nervosa patients 11.7 years after first admission. J Bone Miner Res 8:597-605 
5. 
Grinspoon S, Thomas E, Pitts S, Gross E, Mickley D, Miller K, Herzog D, Klibanski 
A 2000 Prevalence and predictive factors for regional osteopenia in women with anorexia 
nervosa. Ann Intern Med 133:790-794 
6. 
Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A 2005 Medical 
findings in outpatients with anorexia nervosa. Arch Intern Med 165:561-566 
7. 
Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR 1991 The clinical course 
of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 
265:1133-1138 
8. 
Lucas AR, Melton LJ, 3rd, Crowson CS, O'Fallon WM 1999 Long-term fracture risk 
among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc 
74:972-977 
9. 
Riis BJ, Rodbro P, Christiansen C 1986 The role of serum concentrations of sex 
steroids and bone turnover in the development and occurrence of postmenopausal 
osteoporosis. Calcified tissue international 38:318-322 
10. 
Biller BM, Saxe V, Herzog DB, Rosenthal DI, Holzman S, Klibanski A 1989 
Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin 
Endocrinol Metab 68:548-554 
11. 
Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC 1995 The effects of 
estrogen administration on trabecular bone loss in young women with anorexia nervosa. J 
Clin Endocrinol Metab 80:898-904 
12. 
Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A 2002 Effects of 
recombinant human IGF-I and oral contraceptive administration on bone density in 
anorexia nervosa. J Clin Endocrinol Metab 87:2883-2891 
13. 
Weissberger AJ, Ho KK, Lazarus L 1991 Contrasting effects of oral and transdermal 
routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, 
insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin 
Endocrinol Metab 72:374-381 
14. 
Kam GY, Leung KC, Baxter RC, Ho KK 2000 Estrogens exert route- and dose-
dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-
labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85:1918-1922 
15. 
Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB, Jr. 1992 The effect 
of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like 
growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 75:762-
767 
16. 
Elis S, Courtland HW, Wu Y, Rosen CJ, Sun H, Jepsen KJ, Majeska RJ, Yakar S 
2010 Elevated serum levels of IGF-1 are sufficient to establish normal body size and 
skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res 25:1257-1266 
17. 
Elis S, Courtland HW, Wu Y, Fritton JC, Sun H, Rosen CJ, Yakar S 2010 Elevated 
serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis 
is intact. J Bone Miner Res 25:2051-2058 
18. 
Nordstrom SM, Tran JL, Sos BC, Wagner KU, Weiss EJ 2011 Liver-derived IGF-I 
contributes to GH-dependent increases in lean mass and bone mineral density in mice 
with comparable levels of circulating GH. Mol Endocrinol 25:1223-1230 

BWH/DFCI/MGH Human Subjects Research Application Form 
Filename: Detailed Protocol.doc 
Version:  March 2007 
 
 
 
 
Page 11 of 11 
 
19. 
Grinspoon S, Miller K, Coyle C, Krempin J, Armstrong C, Pitts S, Herzog D, 
Klibanski A 1999 Severity of osteopenia in estrogen-deficient women with anorexia 
nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 84:2049-2055 
20. 
Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska-Gluszak U, Srzednicki 
M, Brzezinska A, Zgliczynski W, Sadowski Z 1992 Transdermal 17 beta-estradiol 
combined with oral progestogen increases plasma levels of insulin-like growth factor-I in 
postmenopausal women. Journal of endocrinological investigation 15:533-538 
21. 
Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein 
MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, 
Klibanski A 2011 Physiologic estrogen replacement increases bone density in adolescent 
girls with anorexia nervosa. J Bone Miner Res 26:2430-2438 
22. 
Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A 1996 Effects of 
short-term recombinant human insulin-like growth factor I administration on bone 
turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864-
3870 
23. 
Soyka LA, Grinspoon S, Levitsky LL, Herzog DB, Klibanski A 1999 The effects of 
anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 
84:4489-4496 
24. 
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, 
LaCroix AZ, Margolis KL, Stefanick ML 2007 Postmenopausal hormone therapy and 
risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477 
25. 
Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E 2011 Risk 
of venous thromboembolism from use of oral contraceptives containing different 
progestogens and oestrogen doses: Danish cohort study, 2001-9. Bmj 343:d6423 
26. 
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, 
Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen, Thromboembolism 
Risk Study G 2007 Hormone therapy and venous thromboembolism among 
postmenopausal women: impact of the route of estrogen administration and progestogens: 
the ESTHER study. Circulation 115:840-845